Table 2.
Association between MTHFR polymorphisms and ovarian cancer risk in the New England Case Control Study (NEC), Nurses’ Health Study (NHS), and Mayo Clinic Ovarian Cancer Case Control Study (MAY)
| MTHFR SNP | Controls n (%) | Cases n (%) | MV Adjusted* OR (95% CI) | Pooled† OR (95% CI) | |
|---|---|---|---|---|---|
| C677T (rs1801133) | |||||
| NEC | |||||
| CC | 499 (49) | 427 (40) | 1.00 |  |
|
| CT | 488 (43) | 492 (46) | 1.20 (0.99, 1.44) | ||
| TT | 138 (12) | 140 (13) | 1.22 (0.92, 1.60) | ||
| ptrend | 0.06 | ||||
| NHS | |||||
| CC | 210 (44) | 71 (46) | 1.00 | 1.00 | |
| CT | 217 (45) | 72 (47) | 0.97 (0.65, 1.45) | 1.16 (1.00, 1.35) | |
| TT | 55 (11) | 10 (7) | 0.60 (0.27, 1.30) | 0.95 (0.64, 1.40) | |
| ptrend | 0.33 | ptrend = 0.59 | |||
| MAY | |||||
| CC | 193 (47) | 164 (45) | 1.00 | ||
| CT | 168 (41) | 167 (46) | 1.18 (0.87, 1.59) | ||
| TT | 51 (12) | 33 (9) | 0.83 (0.51, 1.37) | ||
| ptrend | 0.98 | ||||
| A1298C (rs1801131) | |||||
| NEC | |||||
| AA | 534 (49) | 515 (50) | 1.00 |  |
|
| AC | 450 (41) | 430 (41) | 0.96 (0.80, 1.15) | ||
| CC | 109 (10) | 93 (9) | 0.84 (0.62, 1.15) | ||
| ptrend | 0.31 | ||||
| NHS | |||||
| AA | 236 (49) | 68 (44) | 1.00 | 1.00 | |
| AC | 200 (41) | 67 (44) | 1.17 (0.78, 1.75) | 0.97 (0.84, 1.12) | |
| CC | 48 (10) | 18 (12) | 1.39 (0.73, 2.65) | 0.96 (0.75, 1.24) | |
| ptrend | 0.28 | ptrend = 0.58 | |||
| MAY | |||||
| AA | 189 (46) | 173 (48) | 1.00 | ||
| AC | 180 (44) | 149 (41) | 0.90 (0.66, 1.21) | ||
| CC | 43 (10) | 42 (12) | 1.05 (0.65, 1.69) | ||
| ptrend | 0.84 | ||||
*
Multivariate models are adjusted for age, parity, oral contraceptive use, and tubal ligation. Multivariate models used in the MAY analysis did not include tubal ligation.
†
For the C677T pooled estimate, the p for heterogeneity = 0.02. For the A1298 pooled estimate, the p for heterogeneity = 0.19.